2 years ago

SolasCure Raises GBP 10.9 Million in Series B Funding

  • SolasCure, a UK-based biotechnology company, has raised GBP 10.9M in Series B funding led by Seneca Partners

  • The company will use the funds to support the development of Aurase Wound Gel and progress toward further Phase II clinical trials

  • SolasCure offers Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, which aims to accelerate wound debridement.

      • ProblemHealthcare

      "Chronic wounds are a major healthcare issue, causing pain, infection, and disability. Current treatments are often ineffective and time-consuming, leading to a significant burden on patients and the healthcare system."

      Solution

      "SolasCure has developed Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots that helps to accelerate wound debridement, which is the removal of dead tissue from a wound. This innovative technology aims to provide a faster and more effective treatment option for patients with chronic wounds, leading to improved healing outcomes and reduced healthcare costs."

      Covered on